Abstract:The coronavirus family has many pathogens that cause severe human diseases, including SARS, MERS and COVID-19.Starting from the SARS outbreak in 2003, our group has been dedicated to understanding coronavirus Replication-Transcription Complexes (RTCs).During the early part of the COVID-19 outbreak, we rapidly initiated a structural study of SARS-CoV-2 RTCs, aiming to dissect the key mechanisms for SARS-CoV-2 in human cells and provide structural information to discover potent antivirals.With great efforts from our laboratory and outside collaborations, we successfully determined the structure of the central RTC (C-RTC) composed by nsp12 (RNAdependent RNA polymerase, RdRp) with cofactors nsp7 and nsp8 1 , providing the first picture to visualize this key antiviral target.We also elucidated the mechanism of C-RTC catalysis and how remdesivir (RDV) inhibits the synthesis of RNA.This was achieved by determining the structure of C-RTC in complex with the template-product duplex RNA and the active form of RDV 2 .Subsequently, we presented the structure of the elongation RTC (E-RTC), showing how nsp13 (helicase) unwinds the highly-ordered structure in genome to yield the functional template for RNA synthesis in C-RTC 3 .After that, we discovered a key intermediate state of RTC leading towards mRNA capping [Cap(-1)'-RTC], demonstrating the nsp12 NiRAN is indeed the key enzyme to catalyze the second capping action and how it presents nsp9 as an "adaptor" for the further recruitment of capping enzymes into RTC 4 .In a following study, we assembled Cap(0)-RTC by Cap(-1)'-RTC and nsp10/nsp14, showing how the co-transcriptional capping and an in trans backtracking mechanism for proofreading concert in one RTC 5 .In our most recent work, we discovered a previously unknown protein modification -RNAylation on nsp9, and demonstrated nsp12 NiRAN utilizes the RNAylated nsp9 and GTP as substrates to synthesize the GpppA cap core, reasoning a novel RNA capping pathway 6 .We also showed that the nucleotide analogue inhibitors (NAIs) can be linked to nsp9 by NiRAN and thus block the occurrence of RNAylation and GpppA formation, furthering the understanding of the mechanism of action of NAIs.An 'induce-and-lock' mechanism is proposed to design new inhibitors against SARS-CoV-2 RNA capping.These works not only provides a basis to understand SARS-CoV-2 proliferates in the host cells through a structural biology lens, but also sheds new light for antiviral development against rapidly emerging SARS-CoV-2 variants.1

Viral RNA Replication Suppression of SARS-CoV-2: Atomistic Insights into Inhibition Mechanisms of RdRp Machinery by ddhCTP

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase

Mechanistic insights into the activity of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET

A 'deep dive' into the SARS-Cov-2 polymerase assembly: identifying novel allosteric sites and analyzing the hydrogen bond networks and correlated dynamics

Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase

Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase

Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides

RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic

Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge

Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations

A Story of SARS-CoV-2 RNA Capping

Investigation of protein-protein interactions and hotspot region on the NSP7-NSP8 binding site in NSP12 of SARS-CoV-2

RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target

Protein-protein interaction of RdRp with its co-factor NSP8 and NSP7 to decipher the interface hotspot residues for drug targeting: A comparison between SARS-CoV-2 and SARS-CoV

Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-)-cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2

Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir

2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2